About Synlogic
Synlogic (NASDAQ:SYBX) is pioneering the development and commercialization of a promising and innovative field known as synthetic biotics. Harnessing the power of genetically engineered microbes, Synlogic's projects aim to tackle a range of challenges in the medical and health sectors. Their work includes groundbreaking approaches to treat metabolic disorders, infections, and other diseases by manipulating the functions of living cells to perform therapeutic tasks. Their objective is centered on transforming the lives of patients by advancing the science of synthetic biology to produce living medicines that act in a precise, controlled fashion to treat disease at its source. Synlogic's dedication to innovation reflects their commitment to addressing unmet medical needs through the novel realm of synthetic biotics.
Snapshot
Operations
Products and/or services of Synlogic
- Lrabafenogene marselecobac (SYNB1934): This is their most advanced product candidate, currently being studied in a global Phase 3 trial (Synpheny-3) as a potential treatment for phenylketonuria (PKU). PKU is a rare inherited metabolic disorder that affects the body's ability to process the amino acid phenylalanine.
- SYNB6248: This is a product candidate in Phase 1/2a clinical trial for the treatment of homocystinuria (HCU), another rare inherited metabolic disorder.
- SYNB8802: This is a product candidate in preclinical development for the treatment of enteric hyperoxaluria, a condition that causes excessive oxalate production in the gut.
- Synlogic also has programs targeting gout and cystinuria, both of which are rare metabolic disorders.
Synlogic executive team
- Ms. Mary Beth DooleyPrincipal Executive Officer & Principal Financial Officer
- Dr. Timothy K. Lu M.D., Ph.D.Co-Founder & Member of Scientific Advisory Board
- Dr. James J. Collins Ph.D.Co-Founder & Member of Scientific Advisory Board
- Dr. Jose-Carlos Gutierrez-Ramos Ph.D.Advisor